Lindbrook Capital LLC Increases Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Lindbrook Capital LLC lifted its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 19.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 3,519 shares of the company’s stock after purchasing an additional 565 shares during the quarter. Lindbrook Capital LLC’s holdings in Dr. Reddy’s Laboratories were worth $245,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sequoia Financial Advisors LLC increased its position in shares of Dr. Reddy’s Laboratories by 1.1% during the third quarter. Sequoia Financial Advisors LLC now owns 13,793 shares of the company’s stock valued at $922,000 after buying an additional 151 shares during the period. Janney Montgomery Scott LLC grew its position in shares of Dr. Reddy’s Laboratories by 1.7% during the 3rd quarter. Janney Montgomery Scott LLC now owns 12,550 shares of the company’s stock valued at $839,000 after purchasing an additional 214 shares in the last quarter. Desjardins Global Asset Management Inc. increased its holdings in shares of Dr. Reddy’s Laboratories by 7.2% in the fourth quarter. Desjardins Global Asset Management Inc. now owns 3,786 shares of the company’s stock worth $263,000 after purchasing an additional 255 shares during the period. Schonfeld Strategic Advisors LLC raised its position in shares of Dr. Reddy’s Laboratories by 1.5% in the third quarter. Schonfeld Strategic Advisors LLC now owns 20,200 shares of the company’s stock worth $1,351,000 after buying an additional 300 shares in the last quarter. Finally, Schechter Investment Advisors LLC boosted its stake in Dr. Reddy’s Laboratories by 6.8% during the third quarter. Schechter Investment Advisors LLC now owns 4,769 shares of the company’s stock valued at $319,000 after buying an additional 304 shares during the period. 14.02% of the stock is currently owned by institutional investors.

Dr. Reddy’s Laboratories Stock Up 1.3 %

Shares of NYSE:RDY opened at $72.10 on Tuesday. The stock has a market capitalization of $12.03 billion, a P/E ratio of 19.02, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58. The stock’s 50-day moving average price is $74.37 and its 200-day moving average price is $70.31. The company has a current ratio of 2.55, a quick ratio of 1.90 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a 12-month low of $53.12 and a 12-month high of $77.72.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.11. Dr. Reddy’s Laboratories had a return on equity of 20.97% and a net margin of 19.26%. The business had revenue of $867.00 million for the quarter, compared to analyst estimates of $827.81 million. On average, equities analysts anticipate that Dr. Reddy’s Laboratories Limited will post 3.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Barclays boosted their price objective on Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the stock an “overweight” rating in a report on Monday, January 29th. Jefferies Financial Group cut shares of Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a research report on Thursday, January 11th. Finally, StockNews.com raised shares of Dr. Reddy’s Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $80.00.

Dr. Reddy’s Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.